Global Fatty Liver Disease Drugs Market By Type (ALD, NAFLD), By Stages of ALD and NAFLD, By Region, By Country: Opportunities and Forecast (2017-2022)

Date: 16 August 2017

Over the recent years, the global fatty liver disease industry is growing rapidly as the prevalence of fatty liver disease is rising around the world. Globally, the growth in the fatty liver disease market is driven by rising healthcare expenditure, research and development in the pipeline drugs, upcoming NASH drug by 2020.

According to Azoth Analytics research report, “Global Fatty Liver Disease Drugs Market By Type ALD, NAFLD), By Stages of ALD and NAFLD, By Region, By Country: Opportunities and Forecast (2017-2022)”, global market is projected to display a robust growth represented by a CAGR of 22.67% during 2017 – 2022, chiefly driven rising prevalence of diabetes and obesity and rising alcohol consumption all around world.

There are two type of fatty liver disease–Alcoholic Liver Disease and Non Alcoholic fatty liver disease. Alcoholic liver disease growth is due to rise in alcohol consumption around world. Among Alcoholic Liver disease will witness faster growth in the forecasted period on account of introduction of new drugs in NASH by 2020.

The report titled, “Global Fatty Liver Disease Drugs Market By Type ALD, NAFLD), By Stages of ALD and NAFLD, By Region, By Country: Opportunities and Forecast (2017-2022)” has covered and analysed the potential of global fatty liver disease market and provides statistics and information on market size, shares and growth factors.

A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global fatty Liver Disease Market on the basis of Type (Alcoholic liver disease, Non Alcoholic fatty liver disease), By ALD stages (Alcoholic Steatosis, Alcoholic Steatohepatitis), By NAFLD stages (Steatosis, Non Alcoholic Steatohepatitis), By ALD Drug (Opoid Antagonist, Glucocorticoid, Pentoxifyline, Antioxidants,  Granulocyte colony stimulating factor), By NAFLD Drug (Antioxidants Thiazolidinedione, Biguanides, Lipid Lowering agents, FXR receptor agonist, Elafibranoer), By Region (North America, Europe and ROW) and By Country (U.S., Canada, U.K., Germany, France, China, India, Japan, Brazil, Saudi Arabia, South Africa, Brazil).

...